Shirai K, Hikita H, Sakamori R, Doi A, Tahata Y, Sakane S, Kamada Y, Murai K, Nishio A, Yamada R, Kodama T, Nozaki Y, Kakita N, Ishida H, Nakanishi F, Morishita N, Imanaka K, Sakakibara M, Tatsumi T, Miyoshi E, and Takehara T
Background: Patients with advanced fibrosis are at risk for developing hepatocellular carcinoma (HCC) even after hepatitis C virus (HCV) elimination. We previously reported that serum fucosylated haptoglobin (Fuc-Hp) levels increase as the disease progresses from chronic hepatitis to cirrhosis and then HCC. However, it remains unclear whether serum Fuc-Hp levels can stratify the risk of HCC occurrence after a sustained virological response (SVR) is achieved with direct-acting antivirals (DAAs) in patients with advanced liver fibrosis., Methods: Among 3,550 patients with chronic hepatitis C treated with DAAs at Osaka University Hospital and related hospitals, the stored sera of 140 patients who were diagnosed with F3 or F4 by liver biopsy before DAA treatment, achieved SVR, and had no history of HCC were available at both baseline and the end of treatment (EOT). We measured the Fuc-Hp levels in these samples., Results: The median serum levels of Fuc-Hp at EOT were significantly lower than those at baseline. During the 54.4-month follow-up period, 16 of 140 patients developed HCC. Multivariate Cox proportional hazards analysis revealed that high Fuc-Hp at EOT, high body mass index (BMI), and low albumin at EOT were independent risk factors for HCC occurrence. Patients with all three factors-high Fuc-Hp, high BMI, and low albumin-had a higher incidence of HCC than patients without these factors., Conclusions: High serum Fuc-Hp levels at EOT were an independent risk factor for HCC occurrence after SVR. Combined with BMI and albumin, Fuc-Hp can stratify the risk of HCC occurrence among those with advanced fibrosis., Competing Interests: I have read the journal’s policy and would like to include amended declaration regarding competing interests: [Kumiko Shirai is on the speakers’ bureau for AbbVie GK. Hayato Hikita is on the speakers’ bureau for Gilead Sciences, Inc., and AbbVie GK. Ryotaro Sakamori is on the speakers’ bureau for Gilead Sciences, Inc., MSD, and AbbVie GK. Yuki Tahata is on the speakers’ bureau for AbbVie GK. Takahiro Kodama received grants from Gilead Sciences and is on the speakers’ bureau for Gilead Sciences, Inc., MSD, and AbbVie GK. Yasutoshi Nozaki is on the speakers’ bureau for AbbVie GK. Naruyasu Kakita is on the speakers’ bureau for AbbVie GK. Kazuho Imanaka is on the speakers’ bureau for Gilead Sciences, Inc., and AbbVie GK. Mitsuru Sakakibara is on the speakers’ bureau for Gilead Sciences, Inc., and AbbVie GK. Tetsuo Takehara received grants from Gilead Sciences, Inc., MSD, and AbbVie GK and is on the speakers’ bureau for Gilead Sciences, Inc., MSD, and AbbVie GK. All of them don’t have competing interests relating to employment, consultancy, patents, products in development, and marketed products. Furthermore, the present work is not supported by funding from these commercial sources. All other authors declare that they have no conflicts of interest to disclose. This does not alter our adherence to PLOS ONE policies on sharing data and materials., (Copyright: © 2022 Shirai et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)